XOMA Shares Up 150%, but in the Wrong Way
Dilution is a way of life in the biotech industry. The timeline for getting drugs through each phase of development and in front of the FDA for approval takes many years. More often than not, a few handfuls of them. That kind of timeline requires boatloads of cash, and one of the most common ways to get it is by selling additional shares of stock. Today, Brenton Flynn and Max Macaluso outline some of the most recent offerings to hit the market, including one company with a massive 150% increase in shares outstanding since the end of 2011.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article XOMA Shares Up 150%, but in the Wrong Way originally appeared on Fool.com.Brenton Flynn, Max Macaluso, and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.